ClinicalTrials.gg
CompletedNCT00071331Updated May 3, 2012

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

A Phase 3 interventional study of Tolvaptan in Congestive Heart Failure, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 378 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-05-03.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tolvaptan in Heart Failure — none open to participants now, none under way, none of them phase 3. Tolvaptan · Heart Failure.

Enrollment
Largest of 19
3,600 · median 60
Started
2003
with 1 other
Phase 3
4 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
5 of 19
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 19 studies testing tolvaptan in Heart Failure, this one has the largest enrollment, is one of 2 that started in 2003, is one of 4 in phase 3, and was the 3rd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

None of the 19 studies testing tolvaptan in Heart Failure is open now. The open studies under Heart Failure, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing tolvaptan in Heart Failure as a file.
02

Study summary

The purpose of this study is to compare the effectiveness of tolvaptan or placebo in adults with worsening congestive heart failure (CHF).

Read the detailed description

Study Design: Multicenter, randomized, double-blind, placebo-controlled

03

Conditions studied

  • Congestive Heart Failure

Browse trials for

Keywords

  • chronic heart failure
  • heart failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18 years.
  • Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to randomization. Chronic heart failure is defined as requiring treatment for a minimum of 30 days prior to hospitalization.

The subject must have signs of extracellular volume expansion, defined as two or more of the following: a) jugular venous distention; b) pitting edema (>1+); or c) dyspnea.

  • Class III or IV at the time of hospitalization.
  • \< = 40% within one year.

Exclusion criteria

Exclusion Criteria

  • Women who will not adhere to the reproductive precautions as outlined in the form.
  • Positive urine pregnancy test.
  • Inability to provide written informed consent.
  • Cardiac surgery within 60 days of potential study enrollment, excluding percutaneous coronary interventions.
  • Planned revascularization procedures, electrophysiologic (EP) device implantation, cardiac mechanical support implantation, cardiac transplantation, or other cardiac surgery within 30 days following study enrollment.
  • Subjects who are on cardiac mechanical support.
  • History of bi-ventricular pacer placement within the last 60 days.
  • Co-morbid condition with an expected survival less than six months.
  • Subjects with acute ST segment elevation myocardial infarction at the time of hospitalization.
  • History of sustained ventricular tachycardia or ventricular fibrillation within 30 days, unless in the presence of an automatic implantable cardioverter defibrillator.
  • History of a cerebrovascular accident within the last 30 days.
  • Hemodynamically significant uncorrected primary cardiac valvular disease.
  • Hypertrophic cardiomyopathy (obstructive or non-obstructive).
  • CHF due to uncorrected thyroid disease, active myocarditis or known amyloid cardiomyopathy.
  • Subjects with progressive or episodic neurological disease such as multiple sclerosis or history of multiple strokes.
  • History of primary significant liver disease or acute hepatic failure, as defined by the investigator.
  • History of poorly controlled diabetes mellitus.
  • Morbid obesity, defined as > 159 kg (or 350 lbs) or > 40.
  • Supine systolic arterial blood pressure \< 90 mmHg.
  • Serum creatinine > 3.5 mg/dL or > 309.4 mmol/L.
  • Serum potassium > 5.5 mEq/L or > 5.5 mmol/L.
  • \< 9 g/dL or \< 90 g/L.
  • History of and/or idiosyncratic reaction to benzazepine derivatives (such as benazapril).
  • History of drug or medication abuse within the past year, or current alcohol abuse.
  • Inability to take oral medications.
  • Participation in another clinical drug or device trial within the past 30 days.
  • Previous participation in this or any other tolvaptan clinical trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
3,600 participants

Interventions

06

Study locations

378 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • The Heart Center
    Huntsville, Alabama 35801, United States
  • The Heart Group
    Mobile, Alabama 36608, United States
  • Phoenix Memorial Hospital
    Gilbert, Arizona 85233, United States
  • Arizona Heart Institute
    Phoenix, Arizona 85006, United States
  • Saguaro Clinical Research
    Tucson, Arizona 85712, United States
  • Central Arkansas Veterans Healthcare Systems
    Little Rock, Arkansas 72205, United States
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Bakersfield Memorial Hospital
    Bakersfield, California 93301, United States
  • Central Cardiology Medical Center
    Bakersfield, California 93301, United States
  • Cardiology Associates
    Larkspur, California 94939, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • LAC/USC Medical Center
    Los Angeles, California 90033, United States
  • VA Medical Center- W. Los Angeles
    Los Angeles, California 90073, United States
  • Mission Internal Medical Group
    Mission Viejo, California 92691, United States
  • ARI Clinical Trials
    Redondo Beach, California 92077, United States
  • San Diego Cardiac Center
    San Diego, California 92123, United States
  • Pacific Heart Institute
    Santa Monica, California 90404, United States
  • Cardiovascular Consultants Medical Group, Inc.
    Walnut Creek, California 94598, United States
  • Aurora Denver Cardiology Associates
    Denver, Colorado 80218, United States
  • University of Colorado
    Denver, Colorado 80262, United States
  • Heart and Vascular Clinic of North Colorado
    Fort Collins, Colorado 80528, United States
  • Bakus Resesarch
    Norwich, Connecticut 06360, United States
  • Christiana Care Health System
    Newark, Delaware 19718, United States
  • VA Medical Center
    Washington, District of Columbia 20422, United States
  • Florida Cardiovascular Research
    Atlantis, Florida 33462, United States
  • Cardiology Associates of Fort Lauderdale
    Fort Lauderdale, Florida 33308, United States
  • Jacksonville Heart Center
    Jacksonville Beach, Florida 32250, United States
  • Jacksonville Heart Center
    Jacksonville, Florida 32207, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Melbourne Internal Medicine Assoc.
    Melbourne, Florida 32901, United States
  • University of Miami/ Jackson Memorial Hospital
    Miami, Florida 33136, United States
  • Miami Research and Education Foundation
    Miami, Florida 33156, United States
  • Ocala Resarch Institute
    Ocala, Florida 34480, United States
  • Cardiology Research Associates
    Ormond Beach, Florida 32174, United States
  • Charlotte Heart Group Research Center
    Port Charlotte, Florida 33952, United States
  • Cardiovascular Center of Sarasota
    Sarasota, Florida 34239, United States
  • The Heart and Vascular Institute of Florida
    St. Petersburg, Florida 33701, United States
  • Cardiac Disease Specialists PC
    Atlanta, Georgia 30309, United States
  • Atlanta Heart and Vascular Research Group
    Atlanta, Georgia 30342, United States
  • Georgia Heart Specialists
    Covington, Georgia 30014, United States
  • Idaho Cardiology Associates
    Boise, Idaho 83704, United States
  • Idaho Cardiology Associates
    Meridian, Idaho 83642, United States
  • North Shore Cardiologists
    Bannockburn, Illinois 60015, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Midwest Heart Research Found.
    Lombard, Illinois 60148, United States
  • Illinois Heart & Lung Associates
    Normal, Illinois 61761, United States
  • Heart Care Midwest
    Peoria, Illinois 61603, United States
  • The Care Group
    Indianapolis, Indiana 46260, United States
  • Mid America Cardiology
    Kansas City, Kansas 66160, United States
  • Cardiovascular Associates
    Louisville, Kentucky 40205, United States
  • Louisville Cardiology Medical Group
    Louisville, Kentucky 40207, United States
  • The Louisiana Heart Center
    Chalmette, Louisiana 70043, United States
  • Northshore Medical Research
    Covington, Louisiana 70433, United States
  • Leonard J Chabert Medical Center
    Houma, Louisiana 70360, United States
  • Lousiana State University Health Sciences Center
    Shreveport, Louisiana 71103, United States
  • Cardiac Centers of LA, LLC
    Shreveport, Louisiana 71135, United States
  • Androscoggin Cardiology Associates
    Auburn, Maine 04210, United States
  • Northeast Cardiology Associates
    Bangor, Maine 04401, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • MidAtlantic Cardiovascular Associates
    Baltimore, Maryland 21218, United States
  • Midatlantic Cardiovascular Associates
    Baltimore, Maryland 21229, United States
  • MidAtlantic Cardiovascular Associates
    Baltimore, Maryland 21237, United States
  • Midatlantic Cardiovascular Associates
    Bel Air, Maryland 21014, United States
  • Shore Health System
    Easton, Maryland 21601, United States
  • MidAtlantic Cardiovascular Associates
    Towson, Maryland 21204, United States
  • Heart Associates, P.A.
    Towson, Maryland 21286, United States
  • MidAtlantic Cardiovascular Associates
    Westminster, Maryland 21157, United States
  • Primary Care Cardiology Research
    Ayer, Massachusetts 01432, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Medical Center
    Boston, Massachusetts 02215, United States
  • John Dingell VA Medical Center
    Detroit, Michigan 48201, United States
  • Nisus Research
    Petoskey, Michigan 49770, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073-1026, United States
  • Covenant Medical Center
    Saginaw, Michigan 48602, United States
  • Beaumont Hospital
    Troy, Michigan 48085, United States
  • Michigan Heart
    Ypsilanti, Michigan 48197, United States
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota 55416, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic, Division of Cardiology
    Rochester, Minnesota 55905, United States
  • Park Nicollet Heart Center
    St. Louis Park, Minnesota 55426, United States
  • Regions Hospital Cardiology Research
    St. Paul, Minnesota 55101, United States
  • St. Paul Heart Clinic
    St. Paul, Minnesota 55102, United States
  • Cardiology Associates of North Mississippi
    Tupelo, Mississippi 38801, United States
  • Missouri Cardiovascular Specialists
    Columbia, Missouri 65201, United States
  • VA Medical Center- Kansas City
    Kansas City, Missouri 64128, United States
  • St. Louis University
    St. Louis, Missouri 63110, United States
  • Bryan LGH Heart Institute
    Lincoln, Nebraska 68516, United States
  • Heart Consultants
    Omaha, Nebraska 68122, United States
  • New England Heart Institute
    Manchester, New Hampshire 03102, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey 07962-1956, United States
  • University of Medicine and Dentistry of New Jersey
    Newark, New Jersey 07103, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • Garden State Cardiology
    Paramus, New Jersey 07652, United States
  • Albany Associates in Cardiology
    Albany, New York 12212, United States
  • Cardiology Associates, P.C.
    Johnson City, New York 13790, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • St. Vincents Hospital and Medical Center
    New York, New York 10011, United States
  • St. Lukes-Roosevelt Hospital Centers
    New York, New York 10019, United States

Showing the first 100 of 378 sites across 18 countries. Choose a country and city above to see the rest.

07

References and documents

Publications

  • Hejjaji V, Tang Y, Coles T, Jones PG, Reeve BB, Mentz RJ, Spatz ES, Dunlay SM, Caldwell B, Saha A, Tarver ME, Tran A, Patel KK, Henke D, Pina IL, Spertus JA. Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure. Circ Heart Fail. 2021 Sep;14(9):e008284. doi: 10.1161/CIRCHEARTFAILURE.120.008284. Epub 2021 Sep 1. PubMed 34465123 ↗
  • Ter Maaten JM, Valente MA, Damman K, Cleland JG, Givertz MM, Metra M, O'Connor CM, Teerlink JR, Ponikowski P, Bloomfield DM, Cotter G, Davison B, Subacius H, van Veldhuisen DJ, van der Meer P, Hillege HL, Gheorghiade M, Voors AA. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circ Heart Fail. 2016 Jun;9(6):e002845. doi: 10.1161/CIRCHEARTFAILURE.115.002845. PubMed 27266853 ↗
  • Ambrosy AP, Khan H, Udelson JE, Mentz RJ, Chioncel O, Greene SJ, Vaduganathan M, Subacuis HP, Konstam MA, Swedberg K, Zannad F, Maggioni AP, Gheorghiade M, Butler J. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. Circ Heart Fail. 2016 May;9(5):e002458. doi: 10.1161/CIRCHEARTFAILURE.115.002458. PubMed 27140204 ↗
  • Mentz RJ, Greene SJ, Ambrosy AP, Vaduganathan M, Subacius HP, Swedberg K, Maggioni AP, Nodari S, Ponikowski P, Anker SD, Butler J, Gheorghiade M. Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. Circ Heart Fail. 2014 May;7(3):401-8. doi: 10.1161/CIRCHEARTFAILURE.113.000840. Epub 2014 Apr 15. PubMed 24737459 ↗
  • Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE; Everest Investigators. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail. 2013 Jun;19(6):390-7. doi: 10.1016/j.cardfail.2013.04.001. Epub 2013 May 14. PubMed 23743487 ↗
  • Ambrosy AP, Vaduganathan M, Mentz RJ, Greene SJ, Subacius H, Konstam MA, Maggioni AP, Swedberg K, Gheorghiade M. Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. Am Heart J. 2013 Feb;165(2):216-25. doi: 10.1016/j.ahj.2012.11.004. Epub 2012 Dec 29. PubMed 23351825 ↗
  • Allen LA, Gheorghiade M, Reid KJ, Dunlay SM, Chan PS, Hauptman PJ, Zannad F, Konstam MA, Spertus JA. Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life. Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):389-98. doi: 10.1161/CIRCOUTCOMES.110.958009. Epub 2011 Jun 21. PubMed 21693723 ↗
  • O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Pina I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Erratum In: Am Heart J. 2012 May;163(5):900. PubMed 20435194 ↗
  • Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056. PubMed 18992654 ↗
  • Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007 Mar 28;297(12):1332-43. doi: 10.1001/jama.297.12.1332. Epub 2007 Mar 25. PubMed 17384438 ↗
  • Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25. PubMed 17384437 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2003
First posted
Oct 21, 2003
Start
Sep 2003
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Last update
May 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00071331
First posted
Oct 21, 2003
Start date
Sep 2003
Primary completion
Jul 2006
Completion
Jul 2006
Last update
May 3, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion